Is your product the same as Natera's Zenith?

Zenith is powered by MyOme and brings MyOme's genome-first platform to Natera's clinical network.

Both offer the same core diagnostic testing options:

• Rare Disease Exome — analyzes protein-coding regions of the genome

• Rare Disease Genome — analyzes both protein-coding and non-coding regions for a more comprehensive assessment

• Rare Disease Copy Number Analysis (CNA) — detects genome-wide, clinically relevant copy number variants

All tests are built on MyOme's whole genome sequencing backbone, which goes beyond traditional DNA sequencing by using long-read sequencing to simultaneously analyze DNA sequence and methylation patterns to identify disease-related epigenetic signatures. This multi-omic approach helps resolve variants of uncertain significance and supports diagnosis of rare and ultra-rare diseases — reducing the lengthy diagnostic odyssey many patients face.

If you have additional questions, please contact us at myome.com/contact-us.